论文部分内容阅读
目的观察蔗糖铁注射液治疗慢性肾衰竭患者肾性贫血的临床疗效。方法选择维持性血液透析、腹膜透析慢性肾衰竭患者合并肾性贫血者各24例,随机分为四组:血透蔗糖铁治疗组(A组)、血透口服补铁对照组(B组)、腹透蔗糖铁治疗组(C组)与腹透口服补铁对照组(D组),A组、C组应用蔗糖铁注射液静滴8周,B组、D组应用口服琥珀酸亚铁治疗8周,分别观察比较治疗前及用药后患者血红蛋白(Hb)、血细胞比容(Hct)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)的变化以及促红细胞生成素(EPO)用量。结果①四组患者在治疗前年龄、性别、贫血程度、血清铁指标及EPO用量具有较好的匹配;②四组患者治疗后Hb、Hct、Ret、SF、TSAT较治疗前均有升高(P<0.05),且静脉补铁二组治疗后患者Hb、Hct、Ret、SF、TSAT水平升高更明显,贫血伴随症状得到明显纠正,与口服补铁组比较差异有统计学意义(P<0.05)。结论静脉注射蔗糖铁能有效改善慢性肾衰竭患者肾性贫血症状、提高铁利用率及EPO的治疗效果。
Objective To observe the clinical effect of sucrose iron injection on renal anemia in patients with chronic renal failure. Methods A total of 24 patients with renal anemia and chronic hemodialysis patients undergoing peritoneal dialysis were randomly divided into four groups: group A (hemo-sucrose infusion), group B (group B) (C group) and iron supplementation group (D group). Groups A and C were treated with sucrose and iron injection for 8 weeks. Groups B and D were treated with oral ferrous succinate The changes of hemoglobin (Hb), hematocrit (Hct), serum ferritin (SF), transferrin saturation (TSAT) and erythropoietin (EPO) in patients before and after treatment were observed and compared for 8 weeks. Amount. Results ① There was a good match between the four groups before treatment in terms of age, sex, degree of anemia, serum iron index and EPO dosage. ② The Hb, Hct, Ret, SF and TSAT of the four groups were significantly higher than those before treatment P <0.05). The Hb, Hct, Ret, SF and TSAT levels in the two groups of patients after intravenous iron supplementation were significantly higher than those in the oral iron supplementation group (P < 0.05). Conclusion Intravenous injection of sucrose iron can effectively improve renal anemia in patients with chronic renal failure, improve the utilization of iron and EPO treatment.